Karyopharm Therapeutics | Koszty Operacyjne





Koszty Operacyjne Zmiana Data
AbbVie USD 10.81B 13.45B 2025-12
Abbott USD 9.21B 17M 2025-12
Amgen USD 5.9B 773M 2025-12
AstraZeneca USD 16.69B 5.74B 2025-09
BioCryst Pharmaceuticals USD -387.89M 33.7M 2025-09
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
Enanta Pharmaceuticals USD 79.28M 14.26M 2025-06
GlaxoSmithKline GBP 7.18B 1.42B 2025-12
Incyte USD 1.12B 3.53B 2025-12
J&J USD 18.97B 2.38B 2025-12
Karyopharm Therapeutics USD 61.82M 3.24M 2024-12
MacroGenics USD 67M 8M 2025-09
Merck USD 10.16B 558M 2025-12
Nektar Therapeutics USD 85.09M 109.3M 2025-09
Novartis USD 9.86B 115M 2025-09
Novartis USD 9.77B 401M 2025-09
Pfizer USD 12.91B 79.89B 2025-12
Regeneron Pharmaceuticals USD 2.99B 27.97B 2025-12
Roche Holding CHF 21.01B 10.84B 2025-12
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Takeda JPY 1.02T 400.98B 2025-12
Tectonic Therapeutic USD 21.89M 440K 2025-09
TG Therapeutics USD 132.34M 26.04M 2025-09
Ultragenyx Pharmaceutical USD 330.82M 56.44M 2025-09
Xencor USD 68.52M 8.26M 2025-09


Karyopharm Therapeutics Koszty Operacyjne - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - Feb 2026.